Zydus leads glitazar pack with planned Indian launch
This article was originally published in Scrip
Executive Summary
Zydus Cadila is set to introduce on the Indian market Lipaglyn (saroglitazar), the first glitazar molecule to be approved anywhere in the world, for the treatment of dyslipidemia or hypertriglyceridemia not controlled by statins alone in patients with type 2 diabetes.